Another promising strategy for compensating for the lack of ligands associated with activating receptors such as NKG2D is to create recombinant immunoligands that contain antibody fragments targeting antigens that are commonly overexpressed on cancer cells or the extracellular domain of ligands of the NKG2D receptor to interact with host NK cells (Fig. 4B). Here, KLRK1 is linked to cancer.